Distributor inventory | Tablet
Dapagliflozin 10 mg + Sitagliptin 100 mg tablets
Type 2 diabetes mellitus: used as an add-on to diet and exercise to improve glycaemic control in adults when dual therapy is appropriate.
Dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion and lowering blood sugar. Sitagliptin is a DPP-4 inhibitor that increases incretin levels, enhancing insulin release and reducing glucagon in a glucose-dependent manner.
Oral tablet. Usually taken once daily, with or without food, at the same time each day. Follow the dose and duration prescribed by the doctor; do not stop abruptly without advice.
Common side effects of ZUCAPRIDE S 10/100 TAB 15`S may include:
For Type 2 diabetes only (not for Type 1 diabetes). Risk of diabetic ketoacidosis (can occur even with near-normal glucose); seek urgent care for nausea/vomiting, abdominal pain, rapid breathing. May cause dehydration/low BP—use caution in elderly, on diuretics, or with low BP. Increased risk of genital mycotic infections and UTIs. Assess kidney function before and during therapy; not recommended in severe renal impairment/ESRD or dialysis. Rare risk of pancreatitis (sitagliptin)—stop and seek care if severe abdominal pain. Inform doctor before surgery/acute illness; SGLT2 inhibitors are often withheld temporarily.
